MedTrace Logo

Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau

NCT05728736 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-11-08

No results posted yet for this study

Summary

This study will look at the effects of lemborexant on Alzheimer's disease biomarkers found in the cerebrospinal fluid (CSF) and blood in individuals who are poor sleepers

Conditions

  • Alzheimer Disease

Interventions

DRUG

Lemborexant 25 mg

Lemborexant 25mg will be taken nightly for two consecutive nights.

DRUG

Placebo

Placebo will be taken nightly for two consecutive nights

Sponsors & Collaborators

  • Eisai Inc.

    collaborator INDUSTRY

  • Brendan Lucey

    lead OTHER

Principal Investigators

  • Brendan Lucey, MD · Washington University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2023-09-27
Completion
2023-10-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05728736 on ClinicalTrials.gov